Aqr Capital Management LLC Arvinas, Inc. Transaction History

Aqr Capital Management LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$14.19 - $42.33 $241,627 - $720,795	17,028 New	17,028 $700,000
Q4 2022 Feb 14, 2023	SELL	$32.47 - $57.24 $273,559 - $482,247	-8,425 Reduced 52.5%	7,623 $260,000
Q3 2022 Nov 14, 2022	BUY	$41.87 - $57.99 $671,929 - $930,623	16,048 New	16,048 $714,000
Q1 2022 May 16, 2022	SELL	$60.27 - $81.57 $1.29 Million - $1.75 Million	-21,465 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$65.85 - $96.21 $354,470 - $517,898	5,383 Added 33.47%	21,465 $1.76 Million
Q3 2021 Nov 15, 2021	BUY	$73.2 - $107.87 $552,220 - $813,771	7,544 Added 88.36%	16,082 $1.32 Million
Q2 2021 Aug 16, 2021	BUY	$60.45 - $84.26 $17,590 - $24,519	291 Added 3.53%	8,538 $657,000
Q1 2021 May 17, 2021	BUY	$58.19 - $91.37 $479,892 - $753,528	8,247 New	8,247 $545,000
Q4 2020 Feb 16, 2021	SELL	$20.19 - $84.93 $212,075 - $892,104	-10,504 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$22.99 - $36.34 $462,696 - $731,378	-20,126 Reduced 65.71%	10,504 $248,000
Q2 2020 Aug 17, 2020	SELL	$29.88 - $56.74 $428,479 - $813,651	-14,340 Reduced 31.89%	30,630 $1.03 Million
Q1 2020 May 15, 2020	BUY	$33.0 - $54.5 $1.48 Million - $2.45 Million	44,970 New	44,970 $1.81 Million

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.02B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Aqr Capital Management LLC with notifications on news.